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Abstract: Oncolytic Newcastle disease virus (NDV) might be a promising new therapeutic
agent for the treatment of pancreatic cancer. We evaluated recombinant NDVs (rNDVs)
expressing interferon (rNDV-hIFNβ-F0) or an IFN antagonistic protein (rNDV-NS1-F0),
as well as rNDV with increased virulence (rNDV-F3aa) for oncolytic efficacy in human
pancreatic adenocarcinoma cells. Expression of additional proteins did not hamper virus
replication or cytotoxic effects on itself. However, expression of interferon, but not NS1,
resulted in loss of multicycle replication. Conversely, increasing the virulence (rNDV-F3aa)
resulted in enhanced replication of the virus. Type I interferon was produced in high amounts
by all tumor cells inoculated with rNDV-hIFNβ-F0, while inoculation with rNDV-NS1-F0
resulted in a complete block of interferon production in most cells. Inoculation of
human pancreatic adenocarcinoma cells with rNDV-F3aa caused markedly more cytotoxicity
compared to rNDV-F0, while inoculation with rNDV-hIFNβ-F0 and rNDV-NS1-F0 induced
cytotoxic effects comparable to those induced by the parental rNDV-F0. Evaluation
in vivo using mice bearing subcutaneous pancreatic cancer xenografts revealed that only
intratumoral injection with rNDV-F3aa resulted in regression of tumors. We conclude that
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although lentogenic rNDVs harboring proteins that modulate the type I interferon pathway
proteins do have an oncolytic effect, a more virulent mesogenic rNDV might be needed to
improve oncolytic efficacy.
Keywords: oncolytic virus; oncolytic virotherapy; Newcastle disease virus; pancreatic
adenocarcinoma; innate immunity; immunotherapy
1. Introduction
Patients with pancreatic adenocarcinoma still have very poor survival rates, and current therapies are
of limited effect [1,2]. Oncolytic Newcastle disease virus (NDV) could be a promising new therapeutic
agent for the treatment of pancreatic cancer. Newcastle disease virus (NDV) has been described as a
naturally occurring oncolytic virus as early as 1952 [3–5]. Since then, numerous clinical trials have
employed wild type NDV strains either as a direct oncolytic agent, or as an oncolysate vaccine for
treatment of patients with various types of advanced stage cancer [6–11]. Results of these early trials
have been relatively disappointing, illustrated by the lack of further development of these treatment
strategies. With the advent of recombinant DNA techniques it has become possible to genetically
engineer NDV [12], and interest in the use of recombinant NDV (rNDV) as an oncolytic virus has
revived over the last decade [13].
NDV selectively replicates in and destroys tumor cells while sparing normal cells, presumably
because of defective interferon signaling pathways of the innate immune system in tumor cells.
Previously, we reported that a lentogenic wild type NDV strain replicated in and was cytotoxic for
11 human pancreatic adenocarcinoma cell lines (HPACs) with high variability. These differences in the
response of HPACs were not due to defects in innate immunity pathways as a number of these cell lines
produced type I interferon (IFN) upon NDV infection [14]. We, and others, have also shown that IFN
produced by tumor cells and the normal cells surrounding the tumor cells exerts anti-proliferative,
pro-apoptotic and pro-inflammatory effects in tumor cells, possibly attributing to oncolytic efficacy [15–19].
Therefore, rNDVs armed with the IFN gene might result in a virus with higher oncolytic efficacy.
However, the antiviral activity of IFN hampers NDV replication in tumor cells [14]. Viruses use
different strategies to counteract the IFN pathway to increase infectivity and replication efficiency. The
non-structural NS1 protein of influenza A virus is one of the most potent antagonists of the IFN response
of the innate immunity characterized to date [20,21]. Oncolyis of tumor cells depend on efficient virus
infection and replication, therefore, incorporation of an IFN antagonist, such as the NS1 protein of
Influenza A in the genome of rNDV, could be a way to improve the oncolytic efficacy of rNDV.
NDV strains are categorized in three different groups based on the severity of the disease they cause
in birds: lentogenic, mesogenic, and velogenic and this classification correlates with their oncolytic
properties in cancer cells. Increasing the virulence of rNDV has been shown to improve direct oncolytic
efficacy most, resulting in preclinical studies using mesogenic virulent rNDVs expressing transgenes,
such as IFN and the NS1 protein of influenza virus [13]. However, virulent NDV strains pose an
environmental risk, as birds (specifically poultry) are very susceptible to infection with mesogenic or
velogenic strains.
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We hypothesize that arming lentogenic rNDV with IFN-modulating genes, either accelerating or
blocking the IFN response, would improve the oncolytic effect of NDV sufficiently to circumvent using
virulent rNDV with the associated potential biosafety risks. In the present study we compared lentogenic
rNDVs expressing either hIFNβ or the IFN antagonistic protein (NS1) of the Influenza virus with those
of a virulent rNDV (rNDV-F3aa) for direct oncolytic efficacy.
2. Materials and Methods
2.1. pNDV Cloning
A full-length cDNA clone of lentogenic NDV strain La Sota (pNDV-F0) and expression
plasmids pCIneo-NP, pCIneo-P and pCIneo-L, as well as cloning plasmid pGEM-T-PM-cassette
were kindly provided by Ben Peeters from the Central Veterinary Institute of Wageningen UR,
The Netherlands [12,22]. To create a full length rNDV-F0 expressing either GFP, hIFN-β or NS1 protein
of influenza strain A/PuertoRico/8/1934, a DNA fragment containing the open reading frame (ORF)
encoding these proteins was inserted into the intergenic region between the P and M genes of pNDV-F0
flanked by appropriate NDV-specific transcriptional gene-start and gene-end signals. Cloning strategies
resulted in full length NDV genomes that complied with the rule-of-six [23]. To create a full length
NDV cDNA clone with a multibasic cleavage site in the fusion protein, the amino acid sequence of the
protease cleavage site was changed from 112GRQGR↓L117 (lentogenic) to 112RRQRR↓F117 (mesogenic;
pNDV-F3aa) by means of site-directed mutagenesis as described earlier [24]. Full-length NDV plasmids
were sequenced using a 3130xL Genetic Analyzer (Life Technologies, Bleiswijk, The Netherlands) to
exclude incidental mutations that could arise during the cloning process.
2.2. Recombinant Virus Rescue
Recombinant NDVs were rescued using a method adapted from the original method described
previously [12]. Briefly, BSR-T7 cells were transfected with 5 µg full length pNDV, 2.5 µg pCIneo-NP,
1.25 µg pCIneo-P and 1.25 µg pCIneo-L using 10 µL lipofectamine (Life Technologies). Three days
later, 200 µL BSR-T7 supernatant was injected into the allantoic cavity of 10 day old specified pathogen
free (SPF) embryonated chicken eggs. After incubation in a humidified egg incubator at 37 ◦C for
two or three days (mesogenic or lentogenic rNDVs, respectively), allantoic fluid was harvested and
presence of virus demonstrated by hemagglutination assay [25]. Samples displaying hemagglutination
were passaged once more in eggs to increase virus titer, and allantoic fluid was harvested after 2 or
3 days. Pooled fresh allantoic fluid was purified and concentrated by ultracentrifugation at 27.000 rpm
for two h at 4 ◦C using a 30%/60% sucrose gradient. rNDV stocks were stored at −80 ◦C.
Recombinant influenza virus A/PuertoRico/8/34 was rescued and titrated as described before [26].
2.3. Titration of rNDV
Virus stocks were titrated by end point dilution assay in Vero-118 cells, as described before [14].
All infection experiments were performed in the presence of reduced concentration FBS HyClone (3%;
Thermo Fischer Scientific, Breda, The Netherlands), without the addition of exogenous trypsin.
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2.4. Characterization of rNDV
RNA from virus stocks was isolated using the High Pure RNA Isolation kit (Roche, Woerden,
The Netherlands) following the manufacturer’s instructions and reverse transcribed into cDNA using
a two-step protocol, as described before [14]. Amplicons generated with RT-PCR using primers flanking
the P-M intergenic or F protein cleavage site region were sequenced to confirm the sequence of the
inserted gene between the P and M genes and the protease cleavage site of the fusion protein (F0/F3aa).
Expression of NS1 protein was assayed in Vero-118 cells (mock-)inoculated at m.o.i. 3, with either
rNDV-F0, rNDV-NS1-F0 or positive control influenza A/PuertoRico/8/34. Whole cell-lysates taken
18 h post-inoculation were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred to a Hybond-C Extra nitrocellulose membrane (GE Healthcare Life
Sciences, Diegem, Belgium). Membranes were stained for NS1 using primary monoclonal mouse
anti-influenza A NS1 antibody (AB_2011757/sc-130568; 1:1000 dilution; Santa Cruz Biotechnology,
Heidelberg, Germany) and secondary peroxidase-conjugated polyclonal goat anti-mouse antibody
(P0447; 1:2000 dilution; Dako, Heverlee, Belgium) or for β-tubulin using peroxidase-conjugated
monoclonal rabbit anti-β-tubulin antibody (9099; 1:1000 dilution; Cell Signaling Technology, Leiden,
The Netherlands). Chemiluminescent signals were generated using Amersham ECL Prime Western
Blotting Detection Reagent (GE Healthcare Life Sciences) following manufacturer’s instructions and
detected using a ChemiDoc MP system (Bio-Rad, Veenendaal, The Netherlands).
2.5. Cell Lines and Culture Conditions
The HPACs SU.86.86, HPAF-II, BxPC-3, PANC-1, MIA PaCa-2, Hs 700T, CFPAC, Hs 766T,
AsPC-1, and Capan-2 were obtained from the American Type Culture Collection and authenticated using
Short Tandem Repeat profiling [27]. Cells were not used more than 25 passages after thawing. HPACs,
non-neoplastic human lung fibroblasts MRC-5, Vero-118, BSR-T7, and 293T cells were cultured as
described before [14,28].
2.6. Replication Curves
For MIA PaCa-2 cells 3.0 × 106 and for SU.86.86, HPAF-II, BxPC-3, PANC-1 and Hs 700T
1.5 × 106 cells in T25 flasks (Corning, Amsterdam, The Netherlands) were inoculated at m.o.i. 0.1,
in triplicate After a 1 h incubation, cells were washed three times with PBS and fresh medium was
added. At time points 0, 2 12, 24, 48, and 96 h after washing, duplicates of 100 µL supernatant were
collected, mixed with 100 µL 50% (w/v) sucrose, and frozen at −80 ◦C. Samples were titrated by end
point dilution assay in quadruplicate as described before [14].
2.7. RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) for
hIFNβ mRNA
Twenty-four hours after inoculation with rNDV at m.o.i. 3, cells were lysed with 300 µL lysis buffer
of the Total Nucleic Acid Isolation kit (Roche) and RNA was isolated using a MagNA Pure LC machine
(Roche) following the manufacturer’s instructions. qRT-PCR (30 cycles) was performed with 20 µL
RNA in an ABI PRISM 7000 Sequence Detection System (Life Technologies), using TaqMan gene
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expression assay for human IFNβ1 (Hs00277188_s1, Life Technologies). The primers in this assay map
to the extreme 3′ end of the hIFNβ gene (Hs00277188_s1, www.lifetechnologies.com) [29], with the
reverse primer annealing downstream of the stop codon of the hIFNβ coding sequence. This region is
not present in the rNDV-hIFNβ-F0 virus. Therefore, the qRT-PCR assay is not able to detect IFN-mRNA
transcribed from the virus, and the assay will only detect endogenous transcribed IFN-mRNA. To detect
both endogenous and exogenous expressed IFN, primers and probes mapping in the IFN coding region
were used with an in-house developed assay and β-actin was used as household gene). The sequences
of the primers and probes for the IFN-coding region and β-actin have been described before [30].
Results are presented as fold change of inoculated samples versus mock-inoculated samples (duplicates),
calculated using the 2−∆∆CT method [31].
2.8. IFN Measurement with Luciferase Bioassay
Cells were inoculated in triplicate at m.o.i 3 and 24 h post inoculation, supernatants were collected and
assayed for IFN contents using a bioassay as described before [14]. IFN produced by NDV-inoculated
cells is presented as fold change in luminescence compared to mock inoculated cells.
2.9. Cytotoxicity Assay
Quadruplicates of 2 × 104 cells per well in 96-well plates (Corning) were either mock inoculated
or inoculated with rNDV at different m.o.i. (range 0.0001–100). After 48 h, 100 µL fresh medium
was added. At time point 120 h post inoculation, cell viability was determined using the CytoTox 96
Non-Radioactive Cytotoxicity Assay (Promega, Leiden, The Netherlands), as described before [14].
Prism for Windows version 5.03 (GraphPad software, La Jolla, CA, USA) was used to analyze data
using the log(inhibitor) vs. normalized response (variable slope) function to obtain LD50 values. The
extra sum-of-squares F test was used to compare LD50 values. p-values of <0.05 were considered
statistically significant.
2.10. Ethics Statement
All experiments involving animals were conducted strictly according to European guidelines (EU
directive on animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act, 1997).
The experimental protocol was reviewed and approved by an independent animal experimentation ethical
review committee, not affiliated with Erasmus MC (DEC consult number EMC2921).
2.11. Animals and Experimental Design
Groups of 30 athymic nude mice (strain NMRI-Foxn1nu; Charles River, Sulzfeld, Germany) were
injected subcutaneously in their flank with 3 × 106 SU.86.86, BxPC-3 or MIA PaCa-2 cells. Tumor
width (w) and length (l) were measured using a digital caliper (VWR International, Amsterdam, The
Netherlands) and tumor volume was calculated using the modified ellipsoid formula w2 × l/2 [32,33].
Tumors were allowed to grow until the average tumor volume per group reached 50 mm3 (3–5 weeks)
and animals were appointed randomly stratified for tumor size to one of five treatment groups: PBS,
rNDV-F0, rNDV-hIFNβ-F0, rNDV-NS1-F0 or rNDV-F3aa. Animals were injected intratumorally every
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other day for a total of 4 injections with 5× 107 TCID50 rNDV in a total volume of 50 µL or an equivalent
volume PBS. After injection, tumor sizes were recorded two times weekly. Animals were euthanized
if tumor volume exceeded 2000 mm3, non-healing tumor ulcerations or excessive weight loss occurred,
and ultimately 40 days after first injection with rNDV or PBS. Last observed tumor volumes were carried
forward to calculate median volumes per group. Continuous data were compared between the groups
using the Mann–Whitney U-test. One-sided p-values of <0.05 were considered statistically significant.
3. Results
3.1. Cloning, Rescue and Characterization of Recombinant NDVs
Five different rNDVs were generated which were used throughout this study: rNDV-F0,
rNDV-GFP-F0, rNDV-hIFNβ-F0, rNDV-NS1-F0 and rNDV-F3aa (Figure 1a). Amplicons of the P-M
intergenic (Figure 1b) and F protein cleavage site were sequenced to confirm identity of the rNDV
stocks. Upon titration of virus stocks, only infection with rNDV-F3aa lead to syncytia formation in cell
cultures, characteristic for infection with mesogenic NDV (data not shown). In addition, Western blot
assay confirmed the expression of NS1 by rNDV-NS1-F0 (Figure 1c).
3.2. Replication Kinetics of rNDVs
To test whether the expression of additional transgenes or a change in cleavability of the F protein
had an effect on replication kinetics of rNDVs, replication curves were generated for the different viruses
on six different HPACs. HPACs were selected based on replication efficiency of the wild type virus as
reported in our previous study [14].
Upon inoculation, no significant differences were observed for replication of the lentogenic viruses
rNDV-F0, rNDV-GFP-F0, and rNDV-NS1-F0 on all cellsSU.86.86 and PHPAF-II cells supported
replication of these viruses to high titers, while replication was less efficient in the other four cell lines
(Figure 2).
Inoculation with rNDV-hIFNβ-F0 resulted in attenuated replication in all cells, with significant lower
titers in SU.86.86, HPAF-II and BxPC-3 cells compared to inoculation with rNDV-F0.
In contrast, inoculation with the mesogenic virus rNDV-F3aa resulted in efficient multicycle
replication in most cell lines. Inoculation of SU.86.86 with rNDV-F3aa resulted in significant higher
titers at t = 24 compared to those of rNDV-F0 and after this time point titers of rDNV-F3aa declined,
due to the loss of cells as an effect of the efficient replication. Inoculation with rNDV-F3aa of BxPC-3,
Panc-1, MIA PaCa-2, and Hs 700T resulted in significant higher titers at t = 24, 48 and 96 compared
to those of rDNV-F0. Although the titers for rNDV-F3aa in HPAF-II cells were higher than those of the
other viruses in HPAF-II cells these differences were not significant (Figure 2).
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Figure 1. Generation and characterization of rNDVs. (a) Cloning strategy to obtain full 
length NDV plasmids. The nucleotide length of the NDV genome is noted below the plasmid 
names and all full-length plasmids and pGEM-T-PM-cassette are drawn to scale. The  
3'-terminal leader, intergenic regions and 5'-terminal trailer are shown as horizontal lines. 
Gene-end and gene-start sequences in the PM intergenic region are depicted as vertical black 
and white rectangles, respectively. fwd: forward; rev: reverse; nt: nucleotides; pGEM-T: 
plasmid backbone of pGEM-T-PM-cassette; NP: nucleoprotein gene; P: phosphoprotein 
gene; V: accessory V gene; M: matrix gene; F: fusion gene; HN: hemagglutinin-neuraminidase 
gene; L: large protein gene; (b) PCR product of PM intergenic region. RNA of indicated 
rNDV stocks was reverse transcribed into cDNA and the PM intergenic region was amplified 
with RT-PCR using flanking primers; (c) Western blot for expression of NS1 protein. Whole 
cell lysates of Vero-118 cells (mock-) inoculated with indicated viruses were assayed for 
expression of the NS1 protein or tubulin protein. 
Figure 1. Generation and characterization of rNDVs. (a) Cloning strategy to obtain
full length NDV plasmids. The nucleotide length of the NDV genome is noted below
the plasmid names and all full-length plasmids and pGEM-T-PM-cassette are drawn to
scale. The 3′-terminal leader, intergenic regions and 5′-terminal trailer are shown as
horizontal lines. Gene-end and gene-start sequences in the PM intergenic region are
depicted as vertical black and white rectangles, respectively. fwd: forward; rev: reverse;
nt: nucleotides; pGEM-T: plasmid backbone of pGEM-T-PM-cassette; NP: nucleoprotein
gene; P: phosphoprotein gene; V: accessory V gene; M: matrix gene; F: fusion gene; HN:
hemagglutinin-neuraminidase gene; L: large protein gene; (b) PCR product of PM intergenic
region. RNA of indicated rNDV stocks was reverse transcribed into cDNA and the PM
intergenic region was amplified with RT-PCR using flanking primers; (c) Western blot for
expression of NS1 protein. Whole cell lysates of Vero-118 cells (mock-) inoculated with
indicated viruses were assayed for expression of the NS1 protein or tubulin protein.
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Figure 2. Replication kinetics of rNDVs in 6 different human pancreatic adenocarcinoma 
cell lines (HPACs). Cells were inoculated in triplo with m.o.i. 0.1 and samples were taken 
at indicated time points and titrated by end-point dilution assay in Vero-118 cells. Means 
and standard deviations of duplicate titrations are plotted. H.p.i.: hours post inoculation.  
* = p < 0.05 vs. rNDV-F0 (one-way ANOVA + Bonferroni post-test), tested for time points 
24,48 and 96 h.p.i. 
3.2. Modulation of IFN Response by rNDVs 
As IFN has a direct effect on oncolyis, the capacity of the viruses to induce, enhance or block IFN 
production was evaluated. Ten HPACs, as well as Vero cells (lacking the endogenous IFN genes) and 
MRC-5 cells (fully IFN competent), were inoculated with the five different rNDVs and at 24 h after 
inoculation both hIFNβ protein production as well as gene expression levels were measured. The gene 
expression assay for endogenously expressed IFN maps to the extreme 3' end of the hIFNβ gene, with 
Figure 2. Replication kinetics of rNDVs in 6 different human pancreatic adenocarcinoma
cell lines (HPACs). Cells were inoculated in triplo with m.o.i. 0.1 and samples were taken
at indicated time points and titrated by end-point dilution assay in Vero-118 cells. Means
and standard deviations of duplicate titrations are plotted. H.p.i.: hours post inoculation.
* = p < 0.05 vs. rNDV-F0 (one-way ANOVA + Bonferroni post-test), tested for time points
24, 48 and 96 h.p.i.
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As IFN has a direct effect on oncolyis, the capacity of the viruses to induce, enhance or block IFN
production was evaluated. Ten HPACs, as well as Vero cells (lacking the endogenous IFN genes) and
MRC-5 cells (fully IFN competent), were inoculated with the five different rNDVs and at 24 h after
inoculation both hIFNβ protein production as well as gene expression levels were measured. The gene
expression assay for endogenously expressed IFN maps to the extreme 3′ end of the hIFNβ gene, with
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the reverse primer annealing downstream of the stop codon of the hIFNβ coding sequence. This region
is not present in the rNDV-hIFNβ-F0 virus, thus only the endogenous transcribed IFN-mRNA is detected
and not IFN-mRNA transcribed from the rNDV-hIFNβ-F0 virus.
Inoculation with rNDV-F0 or rNDV-GFP-F0 resulted in upregulation of endogenous hIFNβ gene
expression in MRC-5 cells and in eight of the HPACs. No upregulation was observed in in SU.86.86,
MIA PaCa-2 and, as expected, Vero cells. These findings were mostly in agreement with our findings
using wild type NDV, except for BxPC-3 cells [14]. Inoculation with rNDV-hIFNβ-F0 did not
change this pattern of endogenous hIFNβ gene expression. An in-house assay detecting expression
of both endogenous and exogenous IFN genes revealed similar expression levels as detected with the
validated endogenous assay for cells inoculated with rNDV-F0 or rNDV-GFP-F0, but, as expected,
higher expression levels for rNDV-hIFNβ-F0 inoculated cells (data not shown). With this assay,
expression of exogenous expressed hIFNβ mRNA was also detected in rNDV-GFP-F0 inoculated
SU86.86, Mia PaCa-2 and Vero cells, in which endogenous IFN genes are absent or not upregulated
(Figure 3A). Inoculation with rNDV-NS1-F0 resulted in a marked decrease in endogenous hIFNβ gene
expression levels in HPAF-II, BxPC-3, CFPAC, AsPC-1, Capan-2 cells, and MRC-5 fibroblasts, while
no differences were observed in PANC-1 and Hs 766T cells, compared to expression levels in these cells
inoculated with rNDV-F0.
To test whether the differences in expression of the hIFNβ genes also resulted in differences in protein
production, functional IFN protein content was determined in the supernatants of inoculated cells. Due
to biosafety issues, we could not measure IFN in supernatants of cells inoculated with rNDV-F3aa.
Upon inoculation with rNDV-F0, cells demonstrated variation in the extent of IFN production. Six of
the 10 HPACs produced significant less IFN compared to IFN-competent MRC-5 cells, while HPAF-II,
CFPAC, and Hs 766T had a similar range of IFN production. Incorporation of GFP in the genome
of rNDV-F0 did not change this pattern in most HPACs. Only HPAF-II and Hs 766T cells produced
significant less IFN upon inoculation with rNDV-GFP-F0 compared to inoculation with rNDV-F0, while
the opposite was observed for CFPAC cells.
Upon inoculation with rNDV-hIFNβ-F0, all cells produced significant higher amounts of IFN
compared to inoculation with rNDV-F0, due to viral expression of the exogenous hIFNβ gene
(Figure 3b). This exogenously expressed IFN did not induce upregulation of endogenous hIFNβ gene
expression in SU.86.86, MIA PaCa-2 and, of course, Vero-118 cells (as seen in Figure 3a). Inoculation
of HPACs and MRC-5 cells with rNDV-NS1-F0 resulted in a significant decrease of IFN production in
all these cells as compared to cells inoculated with rNDV-F0 (Figure 3b).
3.4. In Vitro Cytotoxicity
To evaluate the effect of increasing the virulence or incorporation of hIFNβ or NS1 in the genome
of rNDV on direct oncolysis, HPACs and MRC-5 fibroblasts were inoculated with serial dilutions of the
viruses and the median lethal dose (LD50) was determined for each rNDV-cell line combination. Mean
LD50 levels for rNDV-F0 and rNDV-GFP-F0 were generally comparable between cell lines, although
SU.86.86, HS 700T, Capan-2 and MRC-5 demonstrated significant lower cytotoxicity upon inoculation
with rNDV-GFP-F0 compared to rNDV-F0, while CFPAC cells demonstrated higher cytotoxicity for
rNDV-GFP-F0 compared to rNDV-F0 (* above green bars in Figure 4). This indicates that incorporation
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of inert transgenes might have some effect on oncolytic efficacy, but with similar variation in reaction
between the different cells.
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Figure 3. IFN responses upon inoculation with rNDVs. Cells were either mock inoculated 
or inoculated with the indicated rNDV at m.o.i. 3. After 24 h: (a) RNA was isolated and 
quantitative real-time polymerase chain reaction (qRT-PCR) was performed for endogenous 
hIFNβ mRNA. Results are presented as fold change gene induction of treated versus mock 
treated cells calculated using the 2−ΔΔCT method [31]. Means and ranges of triplicate 
experiments are plotted; (b) Supernatants were tested for functional IFN protein content 
using an ISRE-luc bioassay [14]. Results are presented as fold change in luminescence 
compared to mock inoculated cells. Means and standard deviations of triplicate experiments are 
plotted. x = p < 0.05 vs. MRC-5 (one-way ANOVA + Bonferroni post-test), * = p < 0.05 vs. 
rNDV-F0 (one-way ANOVA + Bonferroni post-test).  
Figure 3. IFN responses upon inoculation with rNDVs. Cells were either mock inoculated
or inoculated with the indicated rNDV at m.o.i. 3. After 24 h: (a) RNA was isolated and
quantitative real-time polymerase chain reaction (qRT-PCR) was performed for endogenous
hIFNβ mRNA. Results are presented as fold change gene induction of treated versus mock
treated cells calculated using the 2−∆∆CT method [31]. Means and ranges of triplicate
experiments are plotted; (b) Supernatants were tested for functional IFN protein content
using an ISRE-luc bioassay [14]. Results are presented as fold change in luminescence
compared to mock inoculated cells. Means and standard deviations of triplicate experiments
are plotted. x = p < 0.05 vs. MRC-5 (one-way ANOVA + Bonferroni post-test), * = p < 0.05
vs. rNDV-F0 (one-way ANOVA + Bonferroni post-test).
Viruses 2015, 7 2990
Viruses 2015, 7 11 
 
 
Figure 4. Median LD50 upon inoculation with rNDVs. Cells were either mock  
inoculated (not shown; set as 100% viable) or inoculated with rNDV at different m.o.i. (range 
0.0001–100). Cytotoxicity was measured after 5 days by LDH assay and LD50 values were 
calculated. Means and ranges of LD50 calculations are plotted.  * = p < 0.05 as compared  
rNDV-GFP-F0, rNDV-hIFNβ-F0 and rNDV-F3aa compared to rNDV-F0. # =  p < 0.05  , rNDV-
F3aa compared to rNDV-hIFNβ-F0. ^ = p < 0.05  rNDV-F3aa compared to rNDV-NS1-F0. 
Compared to rNDV-F0, expression of NS1 from rNDV-NS1-F0 did not improve the oncolytic effect 
for most cells. Equal LD50 values were detected for rNDV-F0 and rNDV-NS1-F0 for HPAF-II,  
Hs 700T, Hs 766T, and Capan-2 cells, with even higher LD50 values the other cells. Compared to  
rNDV-F0, expression of exogenous IFN from rNDV-hIFNβ-F0 decreased the oncolytic effect 
significantly in SU.86.86 cells and HS766T cells, but increased oncolysis significantly in Mia PaCa-2, 
Capan-2, and MRC-5 cells. Although statistical analyses revealed differences in the oncolytic effect 
between rNDV-GFP-F0, rDNV-NS1-F0 and rNDV-hIFNβ-F0, with variation in the response of the 
different cells, the results shown in Figure 4 demonstrate that inoculation with the more virulent  
rNDV-F3aa results in a clear improvement of the oncolytic effect.  
Inoculation with rNDV-F3aa resulted in a significant increase in oncolysis in all HPACs when 
compared to inoculation with rNDV-F0 (* above purple bars), for 7 out of 10 HPACs (SU.86.86, PANC-1, 
Hs 700T, CFPAC, Hs 766T, AsPC-1, Capan-2) when compared to rNDV-NS1-F0 (^ above red bars), 
and for 7 out of 10 HPACs (SU.86.86, HPAF, BxPC-3, PANC-1, Hs 766T, AsPC-1 and Capan-2) when 
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using US.86.86, BxPC-3, and MIA PaCa-2 cells. Before starting treatment experiments, toxicity of all
viruses was tested in small groups of mice (n = 3), using per group escalating doses starting from 1× 106
TCID50 up to four times 5 × 107 TCID50 injected intravenously or subcutaneously. None of the injected
mice showed adverse effects or excessive weight loss during these experiments, and we concluded it
was safe to inject mice with the highest dose. Additionally, based on a separate pilot experiment, we
decided to inject mice intratumorally with rNDV since this gave better treatment responses compared to
intravenous injection.
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SU.86.86 tumor xenografts were resistant to all rNDV treatments, even to multiple injections with
mesogenic rNDV-F3aa (Figure 5). While BxPC-3 and MIA PaCa-2 tumor xenografts were resistant to
injection with rNDV-F0, rNDV-hIFNβ-F0 and rNDV-NS1-F0, they did respond to injection with the
mesogenic rNDV-F3aa. Treatment with rNDV-F3aa resulted in tumor regression in five out of six animals
and median tumor sizes were significantly smaller starting at day 13 and 10 after the first injection for
BxPC-3 and MIA PaCa-2 tumor xenografts respectively (p < 0.05). Upon necropsy of these animals,
only very small residual tumors were found, as opposed to the mostly large tumors in animals treated
with either PBS or lentogenic rNDVs.
4. Discussion
In our efforts to further develop oncolytic viro-therapy for pancreatic cancer, we focused our attention
on the use of recombinant NDVs. In our previous study, we evaluated the efficacy of a wild type
lentogenic oncolytic NDV strain in a panel of 11 HPACs. This demonstrated a high degree of variation
between the cells in their response to inoculation with NDV, not only in oncolysis but also in activation
of the IFN response [14]. We hypothesized that increasing the oncolytic effects of NDV would
overcome this variability. Various strategies have been reported to improve the efficacy of oncolytic
rNDVs: transfer of therapeutic or immunomodulating transgenes [24,34–37], targeting of tumor cells
with modified attachment proteins [38,39], and increasing virulence by increasing the cleavability of the
F protein [24,35,40–43]. As increased virulence can raise biosafety issues, we aimed to improve the
direct oncolytic effect of non-virulent (lentogenic) rNDVs by expressing IFN modulating genes and we
compared their efficacy with a more virulent (mesogenic) rNDV.
Expression of a non-modulating transgene (GFP) or the NS1 protein of the Influenza virus from
a lentogenic rNDV did not change the replication kinetics of rNDV-F0 in a set of six HPACs, but
expression of high levels of exogenous hIFNβ from rNDV-hIFNβ-F0 hampered virus replication in
susceptible HPACs. This was not surprising, since we showed earlier that HPACs have mostly intact
IFN signaling pathways and replication of NDV is sensitive to IFN treatment [14]. In contrast to
the lentogenic viruses, the mesogenic rNDV-F3aa was capable of multicycle replication in all HPACs
tested. This higher efficiency in replication correlated with the higher cytotoxic effects for NDV-F3aa
in most HPACs, indicating this to be the oncolytic rNDV with the highest oncolytic efficacy. This is in
agreement with other studies that reported on the oncolytic efficacy of mesogenic rNDVs [24,35,40–43].
However, three HPACs (HPAF-II, MIA PaCa-2, and Hs 700T) remained somewhat resistant to
rNDV-F3aa-induced cytotoxicity, and it remains to be determined why some cells are more resistant
than others. Future experiments should elaborate more on the etiology of differences in susceptibility of
HPACs for the oncolytic effect of NDV. These experiments should not only focus on innate immunity,
but also on differences in apoptotic, necrotic, autophagy and/or immunogenic cell death pathways.
Elucidating knowledge on the traits defining susceptibility to NDV induced oncolytic effects would allow
improvement of oncolytic NDV to also attack relatively resistant tumor cells. As previously reported for
wild type NDV, inoculation with rNDV-F0 resulted in IFN production by a number of HPACs, but this
did not always correlate with virus replication kinetics or oncolytic effects induced by rNDV-F0 [14].
Inoculation with rNDV-NS1-F0 resulted in markedly reduced hIFNβ gene expression levels in most
HPACs capable of expressing endogenous hIFNβ and, more interestingly, in almost complete absence
Viruses 2015, 7 2993
of IFN production in almost all HPACs. Indeed, it is known that NS1 of influenza A is a potent
blocker of IFN induction by, among other mechanisms, suppressing RIG-I receptor signaling, IRF3
dimerization and subsequent IFNβ promoter activation [20,21]. Expression of exogenous hIFNβ from
rNDV-hIFNβ-F0 did not lead to increased expression levels of the endogenous hIFNβ gene, but did
result in production of high amounts of hIFNβ protein. This illustrates that lentogenic rNDV-F0 is
very suitable as a (transient) gene therapy vector, as the (additional) production of IFN can only be
attributed to viral hIFNβ gene expression. Interestingly, the lower replication of rNDV-hIFNβ-F0 did
not always result in significant lower cytotoxicity in most HPACs (such as Mia Paca-2 cells), indicating
that hIFNβ might have a cytotoxic effect by itself. A recent publication demonstrated that most
HPACs are susceptible to exogenous hIFNβ treatment, but SU.86.86 cells were found to be relatively
resistant [18]. In line with these findings, inoculation of SU.86.86 cells with rNDV-hIFNβ-F0 lead to
lower cytotoxicity as compared to inoculation with rNDV-F0. Apparently, rNDV-hIFNβ-F0 replication
and resulting cytotoxicity is hampered by the exogenous hIFNβ produced by inoculated SU.86.86 cells,
while SU.86.86 cells are insensitive to the cytotoxic effects of hIFNβ. These findings are also in
line with studies showing that incorporation of IFNβ genes into oncolytic viruses such as vesicular
stomatitis virus or vaccinia virus leads to lower virus replication in cell lines with intact IFN signaling
pathways [44–47], and, previously, we showed that most HPACs do have intact and functional innate
immune pathways [14].
We observed up regulation of hIFNβ mRNA and functional IFN protein production in BxPC-3
cells, which was in conflict with the results of our previous study [14]. Other groups have also noted
an unstable phenotype of BxPC-3 [48] and the difference between our findings in this study and the
previously published one may be attributed to higher passage numbers of BxPC-3 cells used earlier.
Exogenous expression of influenza NS1 protein from rNDV-NS1-F0 did not change replication
kinetics in the inoculated HPACs. However, it did lead to less cytotoxicity in most HPACs, indicating
again that IFN has a cytotoxic effect on these cells. This is in contrast with results reported for a
mesogenic rNDV expressing NS1 (rNDV-NS1-F3aa), which induced enhanced tumor cell killing due
to inhibition of apoptosis, leading to increased syncytia formation [34].
In vivo experiments using a subcutaneous xenograft tumor model using PxPC-3 or MIA Paca-2
cells in immune-deficient mice demonstrated that intratumoral treatment with mesogenic rNDV-F3aa
induced tumor regression or stabilization. In contrast, SU.86.86 tumors, which are highly susceptible for
oncolytic rNDV-F3aa treatment in vitro, did not respond to injection with rNDV-F3aa in vivo. SU.86.86
tumors showed a relatively aggressive growth rate in this mouse model when compared to the other tumor
bearing groups, which might explain why rNDV-F3aa treatment was not successful in achieving tumor
regression or stabilization. These results illustrate again that variation in response and heterogeneity of
tumors contributes to the efficacy of oncolytic viro-therapy. Intratumoral treatment with the lentogenic
viruses did not lead to direct oncolytic effects in this model, indicating that, for direct oncolytic effects,
the mesogenic rNDV-F3aa is most effective.
The immune system is thought to contribute to the efficacy of oncolytic viruses and to efficient
clearance of the virus from healthy cells [19]. In this study we have focused on the direct oncolytic
effects of the virus and the contribution of IFN to this, in absence of the immune system. It might
well be possible that the transgenes expressed by the lentogenic viruses would increase the efficacy in
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an immune competent model, however based on our results we expect a higher efficacy of rNDV-F3aa
in these models. Evaluation of the beneficial effects of the immune system to the oncolytic effects of
rNDV-F3aa needs to be performed in an immune-competent model for pancreatic tumors. Although
transgenic animal models that mimic the natural development of pancreatic tumors have been created, at
the moment these are limited and difficult to employ for evaluation of the efficacy of oncolytic viruses.
In conclusion, expression of exogenous IFN modulating genes from lentogenic rNDVs does not
significantly enhance direct oncolyis induced by these viruses compared to those induced by a more
virulent virus. However, increasing the virulence of rNDV by increasing cleavability of the F protein
lead to a significant improvement of oncolytic activity of recombinant NDV. For further development of
virulent rNDV for oncolytic viro-therapy, the biosafety risks of the virus for birds and poultry should be
addressed. In addition, knowledge should be elucidated on the heterogeneity of pancreatic tumors and
on the traits defining susceptibility to NDV induced oncolytic effects.
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